Vabysmo (faricimab)

faricimab 6 mg/0.05 mL intraocular injection, 0.05 mL syringe · INJECTION · PBS code 14799X

STREAMLINED

What it costs

AU$827.4 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2025-05-01.
• Repeats: 2.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Subfoveal choroidal neovascularisation (CNV)

Continuing treatment

Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist; AND

The condition must be due to age-related macular degeneration (AMD); AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must have previously received PBS-subsidised treatment with this drug for this condition for the same eye.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.